Top High Short Interest Stocks

The High Short Interest Stocks Package is designed for investors and analysts who need predictions for stocks with high short interest that are often very volatile and well known for making explosive upside moves (known as a short squeeze). Such stocks have prices that can potentially move up very quickly as traders with open short positions move to cover. It includes 20 stocks with bullish and bearish signals and indicates the best stocks to buy and sell:

• Top 10 High Short Interest Stocks for the long position
• Top 10 High Short Interest Stocks for the short position

Package Name: High Short Interest Stocks
Recommended Positions: Long
Forecast Length: 14 Days (6/16/22 – 6/30/22)
I Know First Average: 10.05%

In this 14 Days forecast for the High Short Interest Stocks Package, there were many high performing trades and the algorithm correctly predicted 6 out of 10 trades. The top performing prediction from this package was CLVS with a return of 86.18%. Further notable returns came from CVM and OCGN at 16.58% and 9.13%, respectively. The High Short Interest Stocks package had an overall average return of 10.05%, providing investors with a premium of 10.17% over the S&P 500’s return of -0.12%.

Clovis Oncology, Inc., incorporated on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Its commercial product Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP), inhibitor of PARP1, PARP2 and PARP3 approved in the United States by the Food and Drug Administration (FDA), as monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy based on an FDA-approved companion diagnostic for Rubraca.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.